XELOX方案治疗进展期胃癌临床观察

Clinical Observation of XELOX Regimen in Progressive Gastric Cancer

目的:观察XELOX方案治疗进展期胃癌的临床效果和不良反应。方法:将进展期胃癌60例随机分成2组,XELOX组(32例):奥沙利铂130 mg/m2溶于5%葡萄糖注射液250 mL,静脉滴注2 h,第1 d;卡培他滨1 000 mg/m2口服,2/d,第1～14 d。对照(OFL)组(28例):奥沙利铂130 mg/m2,溶于5%葡萄糖注射液250 mL,静脉滴注2 h,第1 d;亚叶酸钙100 mg/m2静脉注射,第2 d,氟尿嘧啶(5-Fu)350 mg/m2静脉注射,第2～6 d。21 d为1个周期。2个周期以上评价疗效,观察不良反应。结果:XELOX组总有效率53.13%,OFL组总有效率为39.29%,两组差异无统计学意义(P>0.05)。XELOX组口腔炎及白细胞减少发生率显著低于OFL组(P<0.05)。结论:XELOX方案治疗进展期胃癌疗效较好,不良反应小,利于门诊用药,值得临床推广。

Objective：To compare the clinical efficacy and the adverse effect between XELOX regimen and OFL regimen in patients with progressive gastric cancer. Methods ： Sixty patients with progressive gastric cancer were randomly divided into XELOX group （ n = 32） and OFL group （n =28）. XELOX regimen：Oxaliplatin 130 mg/m2 in 2-hour i. v. infusion D 1 ,Capecitabinel 000 g/m2 divided in two daily do- ses given from D 1 to D 14,PO;OFLregimen：Oxaliplatin 130 mg/m2 in2-houri, v. infusion,LV100 mg/m2,5-Fu350 mg/m2 D2-6 and the cycles were repeated every 21 days. All patients received two or more cycles. The efficacy and adverse effect were observed. Results：XELOX regimen had 53.13% and OFL regimen had 39.29% effective rates with no statistically significant difference（ P 〉 0.05 ）. The incidence rate of oral inflammation and leukocypenia in XELOX group was Dower than that of OFL group（ P 〈 0.05 ）. Conclusion：The XELOX regimen is effective in AGC with little side-effect and is worth recommending.